Ulrik Schulze
Managing Director & Senior Partner
Zurich
Ulrik Schulze leads Boston Consulting Group’s biopharmaceuticals sector and is a member of the Health Care practice in Switzerland. He is a member of the firm’s Marketing, Sales & Pricing, Operations, Corporate Development, People & Organization, and Strategy practices.
Since joining BCG in 1997, Ulrik has worked intensively with clients in the pharmaceutical, biotechnology, medtech, and private-equity sectors in the US, Europe, and Asia. He has worked globally with management teams of leading global companies as well as ambitious emerging companies and private equity firms. His experience covers the full value chain from R&D and manufacturing to commercial, business development and capital market strategies.
Ulrik’s work has more recently focused on strategy development, M&A, post-merger integration as well as organizational and operational transformations. His experience in corporate strategy includes acquisitions, integrations, licensing, and alignment of strategy with value creation for shareholders.
Before joining BCG, Ulrik worked as a postdoctoral fellow in the chemical engineering and biology departments at the Massachusetts Institute of Technology.
The pandemic has transformed health care. Physicians expect long-term changes in how they interact with biopharma companies.
What happens when longstanding channels of interaction no longer function? Companies are fundamentally changing the way they support the delivery of health care.
In their response to COVID-19, pharma and medtech companies have been true to their purpose. They now face questions that go beyond addressing the virus itself.
BCG has taken a look at how biopharma can succeed in the next decade, and we’ve identified five major business imperatives.
Quantum computing has the potential to significantly accelerate, enhance the quality of, and reduce the costs of drug discovery.
The cyberrisks to the health care industry include more than ransomware and threaten more than hospitals. All kinds of companies and institutions are vulnerable.
Biopharma companies are more focused than ever on the operational performance of clinical development. Benchmarking has identified eight factors associated with improved clinical-development performance.
Read more about What drives operational performance in clinical R&D?
R&D productivity has been declining for decades, but a record 53 new therapeutic drugs approved by the U.S. FDA in 2014 suggest that the biopharma industry's fortunes have changed.
